Improved Long-Term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab

BACKGROUND & AIMS: Monitoring serum concentrations of tumor necrosis factor antagonists in patients receiving these drugs as treatment for inflammatory bowel disease (IBD), also called therapeutic drug monitoring, is performed either after patient loss of response (reactive drug monitoring) or i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Gastroenterol Hepatol
Main Authors: Papamichael, Konstantinos, Chachu, Karen A., Vajravelu, Ravy, Vaughn, Byron P., Ni, Josephine, Osterman, Mark T., Cheifetz, Adam S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5605429/
https://ncbi.nlm.nih.gov/pubmed/28365486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cgh.2017.03.031
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados